MarketCap
SELLAS Life Sciences Group SLS
€ 11.07
3.4%
Facebook
X
Telegram
SELLAS Life Sciences Group Langfristiger Schuldenstrom | SLS
Langfristiger Schuldenstrom Jährlich SELLAS Life Sciences Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 544 K | 544 K | 446 K | 372 K | 198 K | 166 K | 217 K | - | 8.38 M | 16.4 M | 4.74 M | 3.91 M | 2.15 M | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 16.4 M | 166 K | 3.17 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
406 K | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Qilian International Holding Group Limited
QLI
|
241 K | - | -6.08 % | $ 184 M |  China |
 |
Happiness Biotech Group Limited
HAPP
|
102 K | - | 1.35 % | $ 17.8 M | China |
 |
Synthetic Biologics
SYN
|
549 K | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
4.18 M | - | - | $ 2.02 B | USA |
 |
BioXcel Therapeutics
BTAI
|
65 K | $ 1.19 | 5.31 % | $ 14.5 M | USA |
 |
I-Mab
IMAB
|
21.9 M | - | - | $ 866 M | China |
 |
BeyondSpring
BYSI
|
320 K | $ 0.84 | 34.27 % | $ 34.5 M | USA |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
Cerus Corporation
CERS
|
2.9 M | $ 2.98 | 4.93 % | $ 568 M | USA |
 |
Compugen Ltd.
CGEN
|
521 K | $ 2.41 | 4.17 % | $ 225 M |  Israel |
 |
CureVac N.V.
CVAC
|
5.32 M | - | - | $ 867 M |  Germany |
 |
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
773 K | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
8.5 M | - | - | $ 4.9 B |  Britain |
|
Galera Therapeutics
GRTX
|
133 K | - | -32.59 % | $ 7.61 M | USA |
 |
Hepion Pharmaceuticals
HEPA
|
116 K | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
619 K | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | Germany |
|
Champions Oncology
CSBR
|
1.52 M | $ 5.1 | 2.63 % | $ 70.5 M | USA |
 |
Affimed N.V.
AFMD
|
539 K | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
784 K | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
137 K | - | - | $ 12.5 M |  Belgium |
 |
Generation Bio Co.
GBIO
|
13 M | - | - | $ 344 M | USA |
 |
AnaptysBio
ANAB
|
2.08 M | $ 58.47 | 4.37 % | $ 1.68 B | USA |
 |
Anika Therapeutics
ANIK
|
2.05 M | $ 21.5 | 1.56 % | $ 308 M | USA |
 |
Gracell Biotechnologies
GRCL
|
17.5 M | - | - | $ 3.37 B | China |
 |
Aurinia Pharmaceuticals
AUPH
|
1.07 M | $ 15.47 | 1.91 % | $ 2.08 B | Canada |
 |
GlycoMimetics
GLYC
|
435 K | - | 9357.83 % | $ 1.01 B | USA |
 |
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
889 K | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bicycle Therapeutics plc
BCYC
|
2.55 M | $ 3.9 | 0.24 % | $ 270 M | Britain |
 |
Beam Therapeutics
BEAM
|
14.4 M | $ 26.75 | 0.91 % | $ 2.65 B | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
8.57 M | $ 67.36 | 0.99 % | $ 12.9 B | USA |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |